BMS-986393
Phase 3Small molecule
BMS-986393 is one of 32 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPreclinical
BMS-986393
JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Nolvadex
AstraZenecaPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Abecma
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma1 trial
Relapsed or Refractory Multiple Myeloma (RRMM)1 trial
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06615479·440 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BMS-986393. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details